OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, highcholesterol and diabetes, has told DirectorsTalk it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.
The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers. Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes. This will allow us to progress both the supply and longer term commercial aspects in parallel.”
See article in full at DirectorsTalk.com